This article summarized the latest R&D progress of Lonafarnib, the Mechanism of Action for Lonafarnib, and the drug target R&D trends for Lonafarnib.

BioLineRx Discloses FDA Authorization for APHEXDA™ (motixafortide), to Activate Hematopoietic Stem Cells for Gathering and Subsequent Autologous Transplantation in Multiple Myeloma Patients.

This article summarized the latest R&D progress of Ixabepilone, the Mechanism of Action for Ixabepilone, and the drug target R&D trends for Ixabepilone.

The Lymphocyte-activation gene-3 (LAG-3) is located on human chromosome 12 (20p13.3), includes 8 exons, and its corresponding cDNA encodes a membrane protein containing 498 amino acids.

This article summarized the latest R&D progress of Fosaprepitant Dimeglumine, the Mechanism of Action for Fosaprepitant Dimeglumine, and the drug target R&D trends for Fosaprepitant Dimeglumine.

Takeda has shared positive initial results from its Phase 2b trial, on TAK-279, a selective, orally administered TYK2 inhibitor, which is assessed for its efficacy in treating active psoriatic arthritis.

This article summarized the latest R&D progress of Ephedrine Hydrochloride, the Mechanism of Action for Ephedrine Hydrochloride, and the drug target R&D trends for Ephedrine Hydrochloride.

Aptamers are short nucleotide sequences, typically DNA or RNA of 20 to 100 nucleotides.

This article summarized the latest R&D progress of Eliglustat, the Mechanism of Action for Eliglustat, and the drug target R&D trends for Eliglustat.

LSTA1 is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors more effectively.

This article summarized the latest R&D progress of Doripenem, the Mechanism of Action for Doripenem, and the drug target R&D trends for Doripenem.

CSF-1 exerts its effects by binding to a receptor called colony stimulating factor 1 receptor (CSF-1R), also known as c-FMS, leading to a signaling pathway cascade.